Literature DB >> 8777963

Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-la-Mancha (Spain)

M Arévalo1, J Solera, D Cebrian, J Bartolomé, P Robles.   

Abstract

The aim of this study was to investigate the incidence of primary and secondary resistance to antituberculosis drugs and the risk factors associated with the resistance in southeast Spain. Our research was based on the clinical histories of 276 patients, diagnosed as having tuberculosis by positive culture, who were tested for drug susceptibility between January 1988 and October 1994. The clinical histories were checked by two independent investigators. Drug-resistant strains were isolated from 24 patients (8.7%). Among the 239 patients without previous tuberculosis therapy, 7 (2.9%) were drug-resistant. Among the 37 patients with previous therapy, 17 (46%) were drug-resistant. Seventeen of the 276 patients (6.2%) had resistance to a single drug. Primary resistance to isoniazid was 1.7%. Previous treatment for tuberculosis (odds ratio (OR) 39.2; 95% confidence interval (95% CI) 10.2-150); hepatic cirrhosis (OR 104; 95% CI 12.8-847); and age 45 yrs and older (OR 4.80; 95% CI 1.15-20.1) were considered risk factors associated with drug-resistant tuberculosis. We conclude that primary and secondary resistance is low in the southeast of Spain and we recommend that susceptibility testing be performed on initial M. tuberculosis isolated from patients with a history of previous tuberculosis therapy, hepatic cirrhosis or more than 44 yrs of age.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777963     DOI: 10.1183/09031936.96.09020274

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Drug-resistant pulmonary tuberculosis in the Baja California-San Diego County border population.

Authors:  C R Peter; E Schultz; K Moser; M Cox; R Freeman; M Ramirez-Zetina; M R Lomeli
Journal:  West J Med       Date:  1998-10

Review 2.  Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease.

Authors:  Biswajit Chakrabarti; Peter M A Calverley; Peter D O Davies
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

3.  Multidrug-resistant pulmonary tuberculosis among young Korean soldiers in a communal setting.

Authors:  Sei Won Lee; Kyeongman Jeon; Kwang Hyun Kim; Kyung Hoon Min
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

4.  Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain.

Authors:  I Suárez-García; A Rodríguez-Blanco; J L Vidal-Pérez; M A García-Viejo; M J Jaras-Hernández; O López; A Noguerado-Asensio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-02       Impact factor: 3.267

Review 5.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

6.  Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea.

Authors:  Jae Chol Choi; Song Yong Lim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Nam Yong Lee; Young Kil Park; Gil Han Bai; Won Jung Koh
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

7.  Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China.

Authors:  Jiang-Nan Zhao; Xian-Xin Zhang; Xiao-Chun He; Guo-Ru Yang; Xiao-Qi Zhang; Wen-Gen Xin; Huai-Chen Li
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.